The effect of aerobic exercise on hepatotoxicity induced by intratracheal instillation of iron oxide nanoparticles in Wistar rats.
Iron oxide nanoparticles (IONPs) can cause significant health problems due to their unique physicochemical properties and environmental characteristics. They are found as ultrafine particles in ambient air. After inhalation, these particles move from the lung to phagocytosis tissues, especially the liver. The aim of present study was to investigate the effect of concurrent aerobic exercise and IONPs on liver enzymes and histological hepatic appearance. 48 rats were divided into six groups: experimental 1 (aerobic exercise), experimental 2 (nanoparticle, anesthesia), experimental 3 (aerobic exercise, nanoparticles, anesthesia), placebo 4 (distilled water, anesthesia), placebo 5 (aerobic exercise, anesthesia), and control group. In groups 2 and 3, 40 mg/kg/b.w. of IONPs was injected via intratracheal installation every other day for 14 days. Groups 1, 3, and 5 [corrected] run on treadmill for 30 minutes with the intensity of 35-40% VO2max (maximal oxygen consumption) every day. ALT was increased in group 1 but decreased in groups 2 and 3. AST was not significant in any of the groups, while ALP was reduced significantly in groups 2 and 3 (p < 0.05). Histological examination of the liver showed that, in groups 2 and 3, hepatic cells were damaged and also the congestion, inflammation, mononuclear cell infiltration, and ballooning degeneration were occurred. Tissue injuries in group 3 were less than those of group 2. These findings indicated that hepatotoxicity was caused by iron oxide nanoparticles; however, low-intensity aerobic exercise could decrease the damage somewhat.
Department of Exercise Physiology, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran. vasili.mgh@gmail.com.
Azadeh
A
Vasili
Gholamreza
G
Sharifi
Mohammad
M
Faramarzi
Ali
A
Noori
Shora
S
Yazdanshenas
D000280:Administration, Inhalation; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005081:Exercise Therapy / Q000379:methods*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D058185:Magnetite Nanoparticles / Q000008:administration & dosage* / Q000633:toxicity*; D008297:Male; D010805:Physical Conditioning, Animal / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
D058185:Magnetite Nanoparticles